Zifam Pyrex Myanmar Co. Ltd. (ZPM) is a joint venture between Zifam Pinnacle Pty Ltd, a respected Australian pharmaceutical company, and Pyrex Trading Co. Ltd, a leading Myanmar-based healthcare distributor. Formed in May 2015, ZPM was established to manufacture Beta-Lactam antibiotics, and in 2020, expanded to produce General Oral Solid Dosage (OSD) products.
As part of the Zifam Pinnacle Healthcare Group, ZPM is proud to deliver global pharmaceutical standards, locally manufactured in Myanmar, to support national health needs and regional partnerships.
At Zifam Pyrex Myanmar, this is more than a motto — it is our promise to every patient, healthcare provider, and stakeholder we serve. It reflects our unwavering dedication to quality, innovation, and service in every aspect of our operations.
To make Consistently Superior Quality Healthcare Products affordable & available and services that meet customer expectations across Myanmar through current Good Manufacturing Practices, state-of-the-art technology, Continuously upgrading the system, Delivering innovative products, Competent workforce and Efficient management.
Our manufacturing site is located 36 km from Yangon International Airport at the Thilawa Special Economic Zone (SEZ). This site is designed for global-standard pharmaceutical manufacturing and regulatory compliance.
Facility Overview:
– Total Area: 17,000 sqm (4.2 acres)
– Beta-Lactam Block: 5,090 sqm
– General OSD Block: 2,271 sqm
Dosage Forms:
– Beta-Lactam (Tablets, Capsules, Dry Syrup, Dry Powder Injection)
– General OSD (Tablets, Hard Gelatin Capsules, Dry powder)
Raw Materials:
– Procured from regulatory-approved sources
– Stored under controlled warehouse conditions
– Subjected to rigorous QC testing before use
Manufacturing Controls:
– Controlled environments and supervised processes
– Laminar airflow systems during material dispensing
– Real-time in-process testing for early deviation detection
Finished Product Assurance:
– All products undergo physical, chemical, and microbiological analysis
– Evaluated against Pharmacopoeial Standards
– Released only after passing comprehensive QC protocols
Stability & Shelf Life Testing:
– Conducted under varied conditions to determine storage and expiry standards
– Instrument Labs with HPLC, UV, Dissolution apparatus
– Microbiology Labs and Stability Chambers
– Data-driven testing environment ensuring consistent quality
Sustainability:
– Zero-discharge ETP and eco-friendly wastewater reuse
– Solid waste incineration protocols for safety
Occupational Safety:
– Fire hydrant systems, extinguishers, and staff training
– Regular health screenings and EHS workshops
HVAC Controls:
– 42 AHUs ensuring temperature, pressure, and particle control
-18 dehumidifier to better control of temperature and humidity in the manufacturing area
– 90/10 air recirculation with filtration for contaminant prevention
Our team includes:
– Pharmacists, chemists, engineers
– Regulatory affairs, QA/QC experts
– Trained operators and support professionals
All contributing to a culture of excellence driven by shared values and a vision of healthcare advancement.
ZPM’s current and future portfolio includes:
– Anti-infectives
– Nutraceuticals
– Medications for chronic conditions (diabetes, cardiovascular, liver health)
– WHO-compliant essential generics
We are expanding to serve not only Myanmar but also regional and global markets.
We are honored to be part of Myanmar’s pharmaceutical landscape — delivering international-standard medicines that support national healthcare goals, with the assurance of our guiding principle:
“Committed to Excellence”
